Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. BLRX
BLRX logo

BLRX

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

BLRX News

Today's Options Volatility and Implied Earnings Changes - November 24, 2025

Nov 24 2025TipRanks

Options Volatility and Projected Earnings Changes for the Week of November 24 – November 26, 2025

Nov 24 2025TipRanks

BioLineRx Reports GAAP EPS of $0.00, Exceeding Expectations by $0.54; Revenue of $0.43M Falls Short by $0.24M

Nov 24 2025SeekingAlpha

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 24 2025PRnewswire

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

Nov 18 2025PRnewswire

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

Nov 17 2025PRnewswire

BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers

Sep 29 2025PRnewswire

Options Volatility and Implied Earnings Moves Today, August 14, 2025

Aug 14 2025TipRanks

BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14 2025PRnewswire

BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

Aug 07 2025PRnewswire

Jones Trading Upgrades BioLineRx - Depositary Receipt () (BLRX)

May 31 2025NASDAQ.COM

Dow Edges Higher; Dell Shares Fall After Q1 Results

May 30 2025Benzinga

Why Is Nano-Cap BioLineRx Stock Surging On Friday?

May 30 2025Benzinga

Nasdaq Down 100 Points; Chicago PMI Dips In May

May 30 2025Benzinga

BioLineRx Reports Promising Motixafortide Combo Data In PDAC Ahead Of ASCO 2025

May 30 2025NASDAQ.COM

Why UiPath Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket

May 30 2025Benzinga